Frankfurt
31.10.25 | 15:29
3,640 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.10. | Inventiva S.A. - 6-K, Report of foreign issuer | 18 | SEC Filings | ||
| 14.10. | INVENTIVA: Inventiva Announces the Implementation of a New ATM Program | 421 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), October 14, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 10.10. | Piper Sandler reiterates Overweight rating on Inventiva stock ahead of key trial | 3 | Investing.com | ||
| 10.10. | Piper Sandler bestätigt "Overweight"-Einstufung für Inventiva-Aktie vor wichtiger Phase-3-Studie | 5 | Investing.com Deutsch | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 09.10. | Inventiva stock price target raised to $24 from $20 at H.C. Wainwright | 10 | Investing.com | ||
| 09.10. | Stifel bekräftigt "Buy"-Rating für Inventiva und verweist auf einzigartiges Profil von Lanifibranor | 7 | Investing.com Deutsch | ||
| 09.10. | Stifel reiterates Buy rating on Inventiva stock, cites lanifibranor's unique profile | 2 | Investing.com | ||
| 07.10. | INVENTIVA: Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting 2025 | 346 | GlobeNewswire (Europe) | Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 studyPresentation of digital pathology data from preclinical studies with lanifibranor
Daix... ► Artikel lesen | |
| 01.10. | Inventiva Names Andrew Obenshain CEO | 4 | RTTNews | ||
| 01.10. | INVENTIVA: Inventiva Appoints Andrew Obenshain as Chief Executive Officer | 315 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), October 1, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 29.09. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.09. | INVENTIVA: Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update | 619 | GlobeNewswire (Europe) | Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits1 as of June 30, 2025Receipt of the gross proceeds of €115.6 million from the second tranche of the structured... ► Artikel lesen | |
| 29.09. | Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings | 3 | Benzinga.com | ||
| 26.09. | Preview: Inventiva's Earnings | 4 | Benzinga.com | ||
| 24.09. | INVENTIVA: Inventiva to Host Analyst and Investor Event on October 8, 2025 | 328 | GlobeNewswire (Europe) | Program will include an update on the Company's lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient... ► Artikel lesen | |
| 04.09. | INVENTIVA: Inventiva to Participate in Upcoming September Investor Conferences | 413 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), September 4, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 02.09. | Inventiva stock price target raised to $13 from $9 at Guggenheim | 3 | Investing.com | ||
| 02.09. | Guggenheim hebt Kursziel für Inventiva auf 13 US-Dollar an | 6 | Investing.com Deutsch | ||
| 27.08. | Inventiva surges as Piper Sandler issues bullish view citing lead asset | 5 | Seeking Alpha |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT PHARMACEUTICALS | 10,465 | -7,10 % | EyePoint Pharmaceuticals, Inc.: EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| EDWARDS LIFESCIENCES | 72,21 | +0,99 % | Edwards Lifesciences Corp. Q3 Profit Decreases, But Beats Estimates | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) reported earnings for third quarter that Decreased from the same period last year but beat the Street estimates.The company's earnings... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,995 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Yolks Breakfast Signs Franchise Agreement for the City of Edmonton, Alberta | Toronto, Ontario--(Newsfile Corp. - October 31, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 119,50 | +0,08 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 | DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5... ► Artikel lesen | |
| DAIICHI SANKYO | 20,680 | +0,58 % | Daiichi Sankyo H1 Earnings Down, Cuts FY Earnings View, Lifts Revenue Forecast; Stock Down | TOKYO (dpa-AFX) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) on Friday trimmed its earnings forecast for full-year ending March 31, 2026, after reporting weak profit in its... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,570 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma Announces Patent Term Extension for EXXUA | DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 28,000 | +2,19 % | Rigel Gears Up to Report Q3 Earnings: Here's What to Expect | ||
| AUSCANN | - | - | Argent BioPharma Signs $15m Deal to Acquire Key Clinical and IP Assets from AusCann | ||
| TUHURA BIOSCIENCES | 2,180 | +2,83 % | TuHURA Biosciences, Inc./NV - 8-K, Current Report | ||
| NRX PHARMACEUTICALS | 2,740 | +2,24 % | New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group | The show is sponsored programming with commercials featuring LASE Technologies ($LASE), PetVivo ($PETV), Acurx Pharmaceuticals ($ACXP), Synergy CHC ($SNYR), and NewsOut - the video press release company.... ► Artikel lesen | |
| CGN MINING | 0,424 | -0,93 % | CGN MINING Surges 10%+ on High Volume; CGN POWER Softens Post-Results | ||
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,920 | 0,00 % | Dividendenbekanntmachungen (09.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALUMINUM CORPORATION OF CHINA LTD CNE1000001T8 0,1348 HKD 0,0147 EUR AMEREN CORPORATION US0236081024 0,71 USD 0,6037 EUR ANHUI... ► Artikel lesen | |
| FUTURA MEDICAL | 0,035 | 0,00 % | Futura Medical Slides To H1 Loss | ||
| BENCHMARK HOLDINGS | 0,256 | -100,00 % | XFRA 31B: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBENCHMARK HLDGS... ► Artikel lesen | |
| BAYER | 26,950 | +0,30 % | Aktien Frankfurt Ausblick: Kursgewinne - Entspannung zwischen USA und China | FRANKFURT (dpa-AFX) - Nach Anzeichen einer Entspannung im US-chinesischen Handelsstreit zeichnet sich am Montag am deutschen Aktienmarkt ein positiver Wochenauftakt ab. Der X-Dax signalisierte den... ► Artikel lesen |
INVENTIVA SA ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.